Clinical Trials Browser

Phase 1 × ALT-803 × 30 days × Clear all

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck